The antitumor immune response in HER-2 positive, metastatic breast cancer patients

Table 1 Patients' characteristics

Total No of BC patients			14
Age at study entry	range		36–69
(yrs)	median		52.5
Menstrual status	premenopausal		1
(No. of pts)	postmenopausal		13
Previous treatment	None		1
(No. of pts)	Surgery	radical (breast)	13
		biopsy only	1
		liver metastasectomy	2
	Irradiation – postoperative		4
	Systemic therapy	adjuvant	11
		adj./neo-adj. chemoth	9
		adj. endocrine therapy	5
		for metastatic disease	7
Min. time elapsed from discontinuation of previous treatments (days)			28
DFI (months)	range		0–144
	median		26
Histology type of primary tumor		IDC	8
(No. of pts)		ILC	2
		IC	4
Histology grade of primary tumor		1	0
(No. of pts)		2	8
		3	2
		unknown	4
SR status	Negative (ER neg. and PR neg.)		4
(No. of pts)	Positive (ER pos. and/or PR pos.)		10
HER-2 status	Positive (3+, ICH)		14
(No. of pts)
Clinical stage of BC at study entry		Stage IV	14
	1^st disease relapse		7
	2^nd disease relapse		5
	3^rd disease relapse		2
Metastatic involvement		Visceral	14
(No. of pts)
		liver involvement	11
		other organs involvement	8

BC = Breast cancer; DFI = Disease-free interval; IDC = Invasive ductal carcinoma;
ILC = Invasive lobular carcinoma; IC = Invasive carcinoma of unknown histology type;
SR = Steroid receptors; ER = Estrogen receptor; PR = Progesterone receptor;
HER-2 = Human epidermal growth factor receptor type 2.

ISSN: 1479-5876